Mar 31,2024

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Lunit will present seven studies at the AACR 2024 Annual Meeting from April 5 to 10. These studies focus on AI analysis of HER2 mutations and their correlation with protein expression, as well as the potential of CNTN4 as a biomarker for immunotherapy success. Findings suggest personalized treatment strategies for cancer patients with ERBB2 mutations and highlight AI's role in enhancing precision medicine. Lunit's CEO, Brandon Suh, emphasizes the transformative impact of AI in cancer care. Visit booth 808 to learn more about Lunit's innovative solutions.

CONFERENCES

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 26,2024

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

Lunit announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR). The study focuses on the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma (HNSCC) patients. In this phase II randomized clinical trial, 48 HNSCC patients were enrolled, with 24 receiving preoperative durvalumab and 24 receiving a combination of durvalumab plus tremelimumab before surgical resection. The study findings revealed that patients treated with the combination of durvalumab and tremelimumab exhibited significantly better 4-year distant recurrence-free survival (DRFS) compared to those receiving durvalumab monotherapy. Additionally, Lunit SCOPE IO's AI analysis backed the remarkable shift in the tumor microenvironment towards an inflamed phenotype, characterized by increased immune activity within the tumor area, in patients receiving combination therapy. 

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 28,2024

Elekta partners with MSD to enhance kidney cancer care using digital solutions

Elekta announced a partnership with MSD (Merck & Co., USA) to develop digital patient monitoring for people with advanced renal cell carcinoma (RCC), using Elekta’s Kaiku Health solution, a digital platform for patient engagement and reported outcomes monitoring. Elekta, with support from MSD, will develop a digital module for patients, keeping them connected with their care team, and educating them about their disease, the treatment and possible side effects. This module includes comprehensive symptom monitoring and patient support, providing patients with tailored and timely symptom monitoring. In addition, the module offers digital education and support materials created specifically for immuno-oncology (IO)-based combination therapy in advanced RCC. The module will be validated in 2024 in collaboration with multiple leading cancer clinics in Europe.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 18,2024

Researchers Develop Deep Learning Model to Predict Breast Cancer

A new study published in Radiology reveals the development of an interpretable artificial intelligence (AI) model, named AsymMirai, for predicting 5-year breast cancer risk from mammograms. Traditional mammography screening can significantly lower the risk of breast cancer-related mortality, but accurately predicting which women will develop breast cancer remains challenging. While previous AI models, such as Mirai, have shown promise in this regard, their complex reasoning process raises concerns about overreliance and potential misdiagnoses. Lead author Jon Donnelly and colleagues at Duke University developed AsymMirai, a simplified AI method that enhances interpretability compared to Mirai. By analyzing 210,067 mammograms from 81,824 patients, the researchers demonstrated that AsymMirai performs almost as well as Mirai in predicting 1- to 5-year breast cancer risk. AsymMirai's straightforward reasoning process makes it a valuable tool for assisting radiologists in breast cancer diagnosis and risk prediction.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 20,2024

AI-Based App can Help Physicians Find Skin Melanoma

A study led by Linköping University in Sweden tested a mobile app, Dermalyser (AI Medical Technology, Stockholm, Sweden), using artificial intelligence (AI) to analyze images of skin lesions for diagnosing melanoma in primary care settings. Published in the British Journal of Dermatology, the study revealed promising results, showing the app's high precision in identifying melanoma and distinguishing it from harmless lesions. The app detected all melanomas and missed only one precursor, with a 99.5% probability of accurately identifying non-melanoma lesions. While the app's effectiveness is encouraging, further research is needed to evaluate its real-world utility as a decision support tool. The researchers plan to conduct a larger follow-up study in multiple countries to assess the app's performance in active decision-making scenarios.

CLINICAL STUDY

#mobile app

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 19,2024

Owkin and University Hospitals Birmingham collaborate to use AI diagnostics in a study that may diagnose and help treat colorectal cancer quicker

Owkin and University Hospitals Birmingham collaborate for a new five year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer. The first research project in this collaboration aims to evaluate the performance of Owkin’s MSIntuit CRC solution in the United Kingdom across UHB’s cohort of 830 patients with primary colorectal adenocarcinoma. Already CE-marked in the European Union and registered for use by the MHRA, the MSIntuit CRC pre-screening solution assists pathologists in the identification of the Microsatellite Instability (MSI) status of colorectal patients, using a deep learning algorithm on digital histology slides. 

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 14,2024 TOP STORY

Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment

Lunit announced the publication of a new study featuring Lunit SCOPE HER2 and Lunit SCOPE ER/PR, Lunit's AI-powered analyzer of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR). The study aimed to evaluate the role of Lunit SCOPE in enhancing pathologists’ consistency and accuracy of breast cancer molecular subtype classification. Results from the study demonstrated a significant increase in agreement among pathologists on the status of HER2, ER, and PR, especially in cases with intermediate weakly positive expressions. Notably, AI assistance led to an increase in agreement on HER2 status from 49.3% to 74.1%, ER from 93.0% to 96.5%, and PR from 84.6% to 91.5%. Consequently, with AI assistance, the agreement among pathologists in classification of breast cancer molecular subtypes saw an increase from 58.2% to 78.6%.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 18,2024

Lunit Expands Presence in Europe to Deliver AI-powered Cancer Screening Solution to France and Portugal

Lunit has entered into a supply contract with TeleDiag, France's largest teleradiology group, established in 2008. By delivering Lunit INSIGHT CXR, a CE-marked AI-powered solution to detect 10 of the most common lung abnormalities, including lung cancer, Lunit and TeleDiag aim to enhance the accuracy and effectiveness of lung disease detection. As TeleDiag regroups a vast network of over 600 radiologists serving more than 300 medical practices and screening over 600,000 patients annually, the collaboration represents a significant leap forward in the integration of AI technology into the French healthcare system, and for Lunit. Lunit has inked a supply agreement with the central region branch of the Portuguese League Against Cancer (LPCC), to deliver its FDA-cleared and CE-marked AI-powered solution for mammography analysis, Lunit INSIGHT MMG. The central region branch of LPCC plans to analyze about 100,000 mammograms annually for the next three years using Lunit INSIGHT MMG.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024

Jasper Health and Breastcancer.org Announce Partnership

Jasper Health welcomes Breastcancer.org to its Nonprofit Partner Network to strengthen the support for those affected by breast cancer. Breastcancer.org bolsters Jasper Health’s existing 80+ National and Local Nonprofit Network, which supports Jasper’s more than 18,000 members to get connected to programs and services that fit their unique needs. This collaboration benefits both organizations’ communities by opening access to the other’s personalized support programs, research participation, educational resources, and online community forums. Together, Jasper Health and Breastcancer.org aim to empower people to help make important decisions for their lives.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 13,2024

Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients

Jasper Health is proud to announce a strategic collaboration with The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer. This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey. Jasper Health and LLS will work together to enhance access to free care navigation and support, education, and resources for blood cancer patients, ensuring that members have access to the latest information and support services tailored to their needs.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY